Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | EYA2 | O00167 | 1/20 | 0.74 |
| ▸ | APP | P05067 | 1/20 | 0.74 |
| ▸ | ACE | P12821 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13322095 | 1.00 | TDP1 (0.74) | TDP1EYA2APPACEBLM | |
| SCHEMBL16406527 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL13201916 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL13398968 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL3904822 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL12517909 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL10005587 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL6124947 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL19700801 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| SCHEMBL22054415 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| WO-2021155292-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY | LOW PHILIP STEWART (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155288-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY | LOW PHILIP STEWART (US) | 2021-08-05 | — | — | WO | disclosed |
| US-9984711-B2 | Magnetic recording medium and coating composition for magnetic recording medium | FUJIFILM CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170372742-A1 | MAGNETIC TAPE AND MAGNETIC TAPE DEVICE | FUJIFILM CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-9704525-B2 | Magnetic tape | FUJIFILM CORPORATION (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9555139-B2 | Binding ligand linked drug delivery conjugates of tubulysins | ENDOCYTE, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160276076-A1 | MAGNETIC TAPE | FUJIFILM CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160093321-A1 | MAGNETIC RECORDING MEDIUM AND COATING COMPOSITION FOR MAGNETIC RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2016-03-31 | — | — | US | disclosed |
| US-9138484-B2 | Conjugates containing hydrophilic spacer linkers | ENDOCYTE, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140066594-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | CYP11B2, FOLR2, CYP11B1 | TDP1 3532/4885EYA2 3727/4885APP 1851/4885 |
| US-20140066594-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | TDP1 3735/4885EYA2 3449/4885APP 3550/4885 |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | TDP1 4113/4885EYA2 4795/4885APP 3822/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | TDP1 2364/4885EYA2 1972/4885APP 1091/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | TDP1 3735/4885EYA2 3449/4885APP 3550/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | TDP1 4073/4885EYA2 4503/4885APP 1558/4885 |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | TDP1 4073/4885EYA2 4503/4885APP 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.